Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06219629 · ClinicalTrials.gov registry record
Parkinson's Disease Progression Study
A clinical trial of Parkinson Disease, sponsored by Koneksa Health.
- Active
- Registry status
- 82
- Enrollment target
- 10
- Study locations
NCT06219629 is a study of Parkinson Disease that is active but no longer recruiting, run by Koneksa Health. The registered enrollment target is 82 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT06219629, a study of Parkinson Disease, is active but no longer recruiting, sponsored by Koneksa Health.
- ACTIVE NOT RECRUITING
- Registry status
- 82 participants
- Enrollment target
- 10
- Study locations
Study Summary
Disease Progression Study
Conditions Studied
Study Locations (10)
Florida
- Parkinsons Disease And Movement Disorders Center Of Boca Raton - Boca Raton
- Accel Research Sites DeLand - DeLand
- Accel Research Sites St Petersburg-Largo - Largo
- N1 Research LLC - Orlando
Colorado
- University of Colorado Health Neurosciences Center - Aurora
Georgia
- Augusta University Health Movement Disorder Clinic - Augusta
Kansas
- University of Kansas Medical Center Parkinson's Disease and Movement Disorder Center - Kansas City
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Michigan
- Quest Research Institute - Farmington Hills
Nevada
- Cleveland Clinic - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2026-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06219629
The ClinicalTrials.gov registry entry for NCT06219629 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The listed sponsor is Koneksa Health, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06219629 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Florida, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT06219629 about?
NCT06219629 is a clinical study titled "Parkinson's Disease Progression Study". Disease Progression Study
What is the current status of trial NCT06219629?
This trial is currently active not recruiting. The enrollment target is 82 participants. The study started on 2024-02-20. Estimated completion is 2026-02.
What conditions does trial NCT06219629 study?
This clinical trial studies the following conditions: Parkinson Disease.
Who is sponsoring clinical trial NCT06219629?
This trial is sponsored by Koneksa Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06219629 being conducted?
This trial has 10 study locations across Colorado, Florida, Georgia, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.